The Pharma Dispatch is a hand-curated newsletter compiled weekly to go beyond the headlines and bring you the most interesting developments related to the pharmaceutical, biotech and medical research from around the world.

If you enjoy what you read here, please consider forwarding and sharing it to spread the word.

Nido Surgical

Nido Surgical is a medical device company that is developing the CardioPort, a novel platform designed to enable video-endoscopic trans-cardiac surgical repairs inside the beating heart.

Top Investor(s): Broadview Ventures

MatriSys Biosciences

MatriSys leverages advances in skin microbiome research to produce live biological therapeutics (LBTs) that rebalance the normal mix of bacterial species present on the skin, expand good microbes and selectively remove the damaging or pathogenic species.

Top Investor(s): Tech Coast Angels

Jupiter Orphan Therapeutics

Jupiter Orphan Therapeutics develops therapies for rare diseases linked to single gene deficiencies. The company has already defined five pipeline products which of one is already in Phase II.

Top Investor(s): Tarnagulla Ventures

Ceres Nonosciences

Ceres has developed and commercialized a novel nanoparticle technology, the Nanotrap®, which provides biomarker capture and biofluid sample processing capabilities for a wide array of diagnostic applications and sample handling needs.

Top Investor(s): GreyBird Ventures

Biscayne Neurotherapeutics

Biscayne Neurotherapeutics is developing novel drugs for serious central nervous system disorders such as refractory epilepsy. The company’s lead compound – a novel anti-epileptic agent called BIS-001 – is a novel synthetic form of huperzine A, a traditional Chinese medicine that has been used as a treatment for cognitive disorders for centuries.

Top Investor(s): Quark Venture, Mesa Verde Venture Partners

410 Medical

410 Medical recently launched the LifeFlow Rapid Infuser, a device that allows for the rapid delivery of fluids for patients with sepsis or other critical conditions.

Top Investor(s): Bios Partners, Sovereign’s Capital

Captozyme

Captozyme is developing therapeutic enzymes to prevent oxalate kidney stones. These types of stones represent 80 percent of stones formed.

Biolabs

TL Biolabs is advancing a $15 genomic test that provides farmers information on the health, productivity, and fertility of their cows — from early in the animal’s life — to make management and breeding decisions earlier and efficiently.

Top Investor(s): Andreessen Horowitz. Refactor Capital, Josh Buckley, Y Combinator

Exonics Therapeutics

Exonics’ laboratory has demonstrated the ability to use adeno-associated virus (AAV) to deliver a payload based on CRISPR/Cas9 technology that can identify and correct exon mutations that prevent the production of dystrophin, a protein that helps stabilize and protect muscle fibers.

Top Investor(s): CureDuchenne Ventures

Cordex Systems

Cordex Systems is an early stage company that has created a proprietary, innovative and patented SmartCuff TM that is designed to detect the early presence of cardiovascular disease. The technology, which is non-invasive, non-imaging and non-operator dependent, is a point-of-care test that takes less than 10 minutes to perform.

Top Investor(s): Plum Alley Investments, National Institutes of Health, Maryland Technology Development Company, Maryland Industrial Partnerships, et al.

If you made it this far, thanks for reading. I’d love to hear which specific topics or sections you would like to know more about and in general, if you have any suggestions, please do write to me at: [email protected]